Walleye Trading LLC Bei Gene, Ltd. Transaction History

Walleye Trading LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 21, 2023	BUY	$179.87 - $225.13 $40,290 - $50,429	224 New	224 $40,000
Q1 2020 May 15, 2020	SELL	$121.84 - $173.19 $120,012 - $170,592	-985 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$115.78 - $208.34 $69,699 - $125,420	602 Added 157.18%	985 $163,000
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $17,071 - $21,104	-139 Reduced 26.63%	383 $51,000
Q3 2018 Nov 14, 2018	BUY	$152.62 - $189.66 $79,667 - $99,002	522 New	522 $90,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Trading LLC with notifications on news.